HRP20190393T1 - Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b - Google Patents

Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b

Info

Publication number
HRP20190393T1
HRP20190393T1 HRP20190393TT HRP20190393T HRP20190393T1 HR P20190393 T1 HRP20190393 T1 HR P20190393T1 HR P20190393T T HRP20190393T T HR P20190393TT HR P20190393 T HRP20190393 T HR P20190393T HR P20190393 T1 HRP20190393 T1 HR P20190393T1
Authority
HR
Croatia
Prior art keywords
prevention
treatment
virus infection
antibody composition
mutant hepatitis
Prior art date
Application number
HRP20190393TT
Other languages
English (en)
Inventor
Se-Ho Kim
Kwang-Won Hong
Wong-Won SHIN
Ki Hwan Chang
Original Assignee
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation filed Critical Green Cross Corporation
Publication of HRP20190393T1 publication Critical patent/HRP20190393T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20190393TT 2012-07-10 2019-02-28 Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b HRP20190393T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120075063 2012-07-10
PCT/KR2013/006025 WO2014010890A1 (en) 2012-07-10 2013-07-08 An antibody composition for prevention or treatment of mutant hepatitis b virus infection
EP13817251.5A EP2858674B1 (en) 2012-07-10 2013-07-08 An antibody composition for prevention or treatment of mutant hepatitis b virus infection

Publications (1)

Publication Number Publication Date
HRP20190393T1 true HRP20190393T1 (hr) 2019-04-19

Family

ID=49916280

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190393TT HRP20190393T1 (hr) 2012-07-10 2019-02-28 Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b

Country Status (14)

Country Link
US (2) US9683029B2 (hr)
EP (1) EP2858674B1 (hr)
JP (2) JP6113279B2 (hr)
KR (2) KR20160092042A (hr)
CN (2) CN104487090B (hr)
AU (1) AU2013287516B2 (hr)
BR (1) BR112015000474A2 (hr)
CA (1) CA2878155C (hr)
EA (1) EA029321B1 (hr)
ES (1) ES2712686T3 (hr)
HR (1) HRP20190393T1 (hr)
MX (1) MX363256B (hr)
MY (1) MY178496A (hr)
WO (1) WO2014010890A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689434B2 (en) * 2015-10-09 2020-06-23 Xiamen University Antibody against hepatitis B surface antigen and use thereof
CN108624564A (zh) * 2017-03-17 2018-10-09 艾博生物医药(杭州)有限公司 抗乙肝表面抗原的单抗隆抗体的制备和筛选
CN108624565A (zh) * 2017-03-17 2018-10-09 艾博生物医药(杭州)有限公司 一种抗乙肝表面抗原的单抗隆抗体制备和筛选
CN107132357B (zh) * 2017-03-23 2019-11-01 山东大学 一种逆转乙型肝炎病毒慢性感染的抗Tim-3抗体和α-galcer的组合及应用
CN107648602B (zh) * 2017-10-23 2020-09-01 苏州大学 二价乙肝疫苗及其制备方法
SI3897672T1 (sl) * 2018-12-20 2024-02-29 Humabs Biomed Sa Kombinirana terapija HBV
KR20220117627A (ko) * 2021-02-17 2022-08-24 주식회사 녹십자 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
FR2815634B1 (fr) 2000-10-20 2003-10-31 Biomerieux Sa Anticorps monoclonaux diriges contre des virus de l'hepatite b
KR100467706B1 (ko) 2002-01-15 2005-01-24 주식회사 녹십자홀딩스 Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP2319917A3 (en) 2002-02-07 2012-02-08 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (en) * 2002-04-12 2008-04-16 Melbourne Health HEPATITIS B VIRUS VARIANTS WITH REDUCED SENSITIVITY TO NUCLEOSIDANALOGES AND USE THEREOF
CN1600856A (zh) 2003-09-26 2005-03-30 陕西九州科技股份有限公司 分泌抗乙肝人单克隆抗体的异种杂交瘤细胞系的构建方法
AU2005330672B2 (en) * 2005-04-18 2011-07-28 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
KR20090056543A (ko) 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체

Also Published As

Publication number Publication date
CA2878155A1 (en) 2014-01-16
MY178496A (en) 2020-10-14
CN104487090B (zh) 2017-06-16
ES2712686T3 (es) 2019-05-14
BR112015000474A2 (pt) 2017-11-14
EA029321B1 (ru) 2018-03-30
AU2013287516B2 (en) 2016-07-07
MX2015000349A (es) 2015-09-29
US20150166637A1 (en) 2015-06-18
EA201500114A1 (ru) 2015-05-29
US20170260257A1 (en) 2017-09-14
CN104487090A (zh) 2015-04-01
EP2858674A1 (en) 2015-04-15
CA2878155C (en) 2019-01-08
KR20160092042A (ko) 2016-08-03
US9683029B2 (en) 2017-06-20
EP2858674B1 (en) 2019-01-30
EP2858674A4 (en) 2015-12-23
KR101653261B1 (ko) 2016-09-12
JP2017095504A (ja) 2017-06-01
KR20150029699A (ko) 2015-03-18
CN107375924A (zh) 2017-11-24
AU2013287516A1 (en) 2015-01-29
JP6113279B2 (ja) 2017-04-12
WO2014010890A1 (en) 2014-01-16
MX363256B (es) 2019-03-19
JP2015527317A (ja) 2015-09-17

Similar Documents

Publication Publication Date Title
HK1203944A1 (zh) 用於治療和預防乙型肝炎病毒感染的 -甲基-二氫嘧啶類
HK1197026A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
HRP20190393T1 (hr) Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b
HK1219480A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的 -橋連的雜芳基二氫嘧啶
HK1210152A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection 6-
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
ZA201205547B (en) Therapies for treating hepatitis c virus infection
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
LT2893936T (lt) Glutarilo histaminas, skirtas ligų, sukeltų (+)rna turinčiais virusais, gydymui ir profilaktikai
IL236476A0 (en) Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it
HK1213816A1 (zh) 治療 型肝炎病毒感染的醫藥組合物
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
HK1201181A1 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
HK1206594A1 (en) Materials and methods for prevention and treatment of viral infections
HK1205680A1 (en) Agent for the treatment of hepatitis c virus
ZA201306878B (en) Treatment of hepatitis c virus infection with alisporivir
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses
SG10201602184TA (en) Treatment of hepatitis c virus infection with alisporivir
AU2012905097A0 (en) Agents and methods for inhibiting virus infection